Get the latest news on CONX stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on CNXX performance

Latest CONX Stock News | OTC:CNXX | Benzinga

CONX Corp

Piper Sandler analyst Joseph Catanzaro maintains Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) with a Neutral and lowers the price target from $7.5 to $6.

News

Price Target

Analyst Ratings

IOVA

Piper Sandler Maintains Neutral on Iovance Biotherapeutics, Lowers Price Target to $6

WIIM

DCGO

DocGo shares are trading lower after the company reported worse-than-expected Q4 financial results.

CUBE

CubeSmart shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS and sales estimates.

Piper Sandler analyst Sean Wieland maintains Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Overweight and raises the price target from $25 to $40.

PRVA

Piper Sandler Maintains Overweight on Privia Health Gr, Raises Price Target to $40

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/TGT/earnings">opening bell, on Tuesday, March 4.</a>
Analysts expect the retailer to report quarterly earnings at $2.25 per share, down from $2.98 per share in the year-ago period. Target projects quarterly revenue of $30.85 billion, compared to $31.92 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 26, JP Morgan analyst Christopher Horvers maintained Target with a Neutral and raised the price target from $139 to $146.
With the recent buzz around Target, some investors may be eyeing potential gains from the company's dividends too. As of now, Target offers an annual dividend yield of 3.61%, which is a quarterly dividend amount of $1.12 per share ($4.48 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $164,028 or around 1,339 shares. For a more modest $100 per month or $1,200 per year, you would need $32,830 or around 268 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.48 in this case). So, $6,000 / $4.48 = 1,339 ($500 per month), and $1,200 / $4.48 = 268 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
TGT Price Action: Shares of Target fell 1.2% to close at $122.50 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/44018351/top-3-utilities-stocks-you-may-want-to-dump-in-february">Top 3 Utilities Stocks You May Want To Dump In February</a></li>
</ul>
Photo: Shutterstock

Earnings

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Target Stock Ahead Of Q4 Earnings

Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) with a Neutral and raises the price target from $75 to $84.

SOLV

Piper Sandler Maintains Neutral on Solventum, Raises Price Target to $84

PRAX

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Tencent Music Entertainment shares are trading lower after the company announced board changes.

PRGO

Perrigo Company shares are trading higher after the company issued FY25 adjusted EPS guidance above estimates.

<a href="https://investors.biogen.com/news-releases/news-release-details/committee-medicinal-products-human-use-chmp-reaffirms-positive">https://investors.biogen.com/news-releases/news-release-details/committee-medicinal-products-human-use-chmp-reaffirms-positive</a> Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Aβ monoclonal antibody lecanemab, adopted in November 2024.1 Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission (EC), the EC will resume the decision-making process for lecanemab's marketing authorization.
In January 2025, as part of its decision-making process, the EC asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in November 2024 and whether this may require an update of the opinion, and to consider whether the wording of the risk minimization measures in the opinion is clear enough to ensure correct implementation. After reviewing the additional information, the CHMP concluded that its positive opinion for lecanemab does not need to be updated.
Mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and AD dementia currently affects an estimated 15.2 million and 6.9 million people in Europe, respectively.2 AD progresses over time in stages with increasingly severe symptoms that greatly impact not only those who are living with AD, but also their loved ones, care partners and society. There is a significant unmet need for new treatment options that slow down the progression of AD from its early stage.
If the EC approves the lecanemab marketing authorization application, the approval will apply to all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. Eisai and Biogen will continue to make every effort to deliver lecanemab to patients with early AD in Europe as soon as possible.
Eisai serves as the lead for lecanemab's development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

Biotech

Global

General

BIIB

The CHMP Reaffirms Positive Opinion For Lecanemab In Early Alzheimer's Disease

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) with a Overweight rating and announces Price Target of $48.

Initiation

AVTX

Piper Sandler Initiates Coverage On Avalo Therapeutics with Overweight Rating, Announces Price Target of $48

RDNT

RedNet shares are trading lower after the company issued FY25 revenue guidance below estimates.

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
The SPY is currently trading around our key level of 587.31. For buyers to remain in control, we want to see a push above 589.71. If this level is established as support, momentum could drive the price toward 592.00. Holding above 592.00 would set the stage for an attempt at 593.73. If buying pressure remains strong, the high bull target for the day is 595.14.
If 587.31 fails to hold as a support level, sellers will aim to challenge 585.75. A breakdown below this level could open the door to 584.68. If selling intensifies, we're watching 583.18 as a key area of interest. Should the market see a sharp decline, the low bear target for the session is 581.97.
Invesco QQQ Trust Series 1 (QQQ)
The QQQ is currently trading near 501.07, which serves as a key pivot point. Bulls need to maintain strength above 502.65 to push toward 504.44. A successful defense of this level could lead to further upside toward 506.68. Should buying momentum remain strong, we anticipate a test of 508.22. If bullish sentiment prevails, the high bull target for the day sits at 509.87.
If the price struggles to hold above 501.07, bears will aim to drive the auction lower toward 499.44. A breakdown of this level could bring 498.37 into play. If sellers gain control, we're looking for a test at 496.94. A sustained sell-off would bring the price down to our low bear target of 495.35.
Apple Inc. (AAPL)
Apple is currently trading around 238.63. Bulls need to maintain strength above 239.43 to see an initial push to 240.23. If this level holds firm, further buying pressure could drive the price toward 241.23. A strong continuation move would target 242.21 as the high bull objective for the session.
If Apple fails to sustain 238.63 as support, we expect a drop toward 237.49. Continued weakness could lead to a test of 236.69. If sellers dominate the action, 235.74 will be a key downside level. A breach of this area could push the stock lower to the low bear target of 234.97.
Microsoft Corp. (MSFT)
Microsoft is currently trading near 392.49. Bulls need to hold above this level to attempt a move toward 393.47. If 393.47 is reclaimed as support, buyers could push the price to 394.46. Should buying momentum persist, our high bull target for the day is set at 395.68.
If 392.49 is lost as support, sellers will look to push the stock down to 390.98. A break below this level would bring 389.29 into focus. If the market remains weak, we expect further downside to 388.53. If aggressive selling takes over, the low bear target for the session is 387.60.
NVIDIA Corporation (NVDA) NVIDIA is currently trading near our level of 120.27. If bulls can push the price to 121.97 and establish it as support, we could see a move toward 123.41. Sustained buying could fuel further upside, targeting 125.21. Should the rally continue, the high bull target for the session is 126.84.
If 120.27 fails to hold, sellers will attempt to push the price toward 119.44. A break below this level could bring 117.86 into play. If bearish momentum persists, we expect a test of 116.61. A decisive breakdown below this level could send the auction to our low bear target of 115.83.
Alphabet Inc Class A ( GOOGL)
Alphabet is currently hovering around 169.34. Bulls need to hold this level and push the price to 171.14. If buyers remain in control, we could see a move toward our high bull target of 172.28.
If 169.34 fails as support, sellers will likely drive the price down to 167.04. A break below this level could lead to a test at 165.41. If selling pressure intensifies, our low bear target for the day is 163.79.
Meta Platforms Inc (META)
Meta is trading around 663.33. Bulls need to maintain strength above this level to push toward 667.99. A strong buying response could drive the price up to 671.80. If buyers continue to dominate, the high bull target is 676.46.
If 663.33 is lost as support, we expect the auction to decline toward 658.86. Further selling could lead to a test of 655.54. If downside pressure remains heavy, the stock may drop to the low bear target of 650.56.
Tesla Inc. (TSLA)
Tesla is currently trading around 281.32. Bulls need to push the price above 283.95 to establish momentum. If this level holds, we could see a rally toward 286.34. Continued buying could bring 288.80 into play. If strength persists, our high bull target is 290.47.
If Tesla fails to maintain 281.32 as support, sellers will aim for 279.43. A breakdown of this level could bring 278.11 into focus. If selling accelerates, we're watching for a move toward our low bear target of 272.42.
Final Word:
Today's session is set to be highly volatile with key economic data releases. The PCE Price Index for January drops at 8:30 AM ET alongside Personal Income, Personal Spending, and Preliminary Wholesale Inventories. At 9:45 AM ET, the MNI Chicago PMI for February will be released, providing insight into Midwest business activity. At 11:00 AM ET, the Kansas City Fed Services Activity report will be out. Additionally, Chicago Fed President Austan Goolsbee, a voting member, is set to speak at 10:15 AM ET, which could impact market sentiment.
Given the combination of economic reports, month-end flows, and the expiration of weekly options, traders should brace for potential sharp moves in either direction. Liquidity conditions may shift rapidly, so risk management remains crucial. Expect elevated price swings and stay agile in response to market developments. Trade smart, and Happy Friday!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Technicals

How To Trade Nvidia Today?

Pearson, Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSO#NYSE">PSO</a>) shares are trading higher premarket on Friday after the company disclosed the expansion of its partnership with Amazon Web Services, Inc. <a href="https://www.benzinga.com/pressreleases/25/02/n44034581/pearson-and-aws-announce-collaboration-to-unlock-ai-powered-personalized-learning-for-millions-of-" target="_blank" rel="noreferrer noopener">to accelerate AI-driven learning solutions</a>.
This collaboration seeks to enhance the learning experience for millions worldwide by leveraging cloud and AI tools to personalize education and provide real-time insights.
Through this partnership, AWS and Pearson will work together to drive the adoption of technology-driven education, aiming to make learning more effective, efficient, and accessible.
Pearson plans to expand its use of AWS cloud infrastructure and AI capabilities, including Amazon Bedrock, to further optimize and scale its learning products and services, particularly in higher education.
Additionally, Amazon and AWS will strengthen their partnership with Pearson VUE to expand cloud training and credentialing, helping organizations drive productivity and accelerate innovation.
Pearson CEO&nbsp;Omar Abbosh&nbsp;said,&nbsp;&#8220;As technology transforms the way we learn, improving people&#8217;s ability to learn is vital for an adaptive workforce.&#8221;
&#8221;With the help of AWS, Pearson will be able to get there faster, scale personalized learning, and create more access to AI tools for learners and educators. This partnership brings together two respected and leading companies in the fields of technology and learning.&#8221;
Also, in a separate release, the company reported underlying sales growth&nbsp;of 3% in FY24, excluding OPM&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n44034472/pearson-2024-preliminary-results-unaudited" rel="noreferrer noopener">and the Strategic Review&nbsp;businesses</a>.
Adjusted EPS increased by 7%, while revenue decreased on a Statutory&nbsp;basis.
For 2025, the company expects a positive outlook<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> for&nbsp;2025 in line with market expectations</a>.
Beyond 2025, Pearson expects a mid-single-digit compound annual growth rate (CAGR) in underlying sales, sustained margin improvement with an average increase of 40 basis points per year, and strong free cash flow conversion, averaging <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">between 90% and 100% over the period</a>.
Omar Abbosh, Pearson&#8217;s&nbsp;Chief Executive, said, &#8220;We are pleased to announce our intention to commence a £350m share buyback programme. This initiative underscores our strong cash position and confidence in Pearson&#8217;s future.&#8221;
Price Action: PSO shares are up 0.83% at $17.00 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44034215" target="_blank" rel="noreferrer noopener">Rocket Lab Unveils &#8216;Flatellite:&#8217; Low-Cost, Mass-Producible Satellite To Target Large Constellations Amid Weak Q1 Guidance</a></li>
</ul>
Photo via Shutterstock.

Guidance

Movers

Pearson Reports Mixed FY24, Expands Partnership With Amazon

HP shares are trading lower after the company issued Q2 adjusted EPS guidance below estimates.

Piper Sandler analyst Matt O'Brien downgrades Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Overweight to Neutral and lowers the price target from $255 to $140.

Downgrades

Piper Sandler Downgrades Teleflex to Neutral, Lowers Price Target to $140

LMAT

LeMaitre Vascular shares are trading lower after Barrington Research downgraded the stock from Outperform to Market Perform.

IBRX

ImmuniyBio shares are trading higher after the company announced it received FDA RMAT Designation for ANKTIVA(R) and CAR-NK.

LOGI

Logitech shares are trading lower after BOA downgraded its rating on the stock from neutral to underperform and its price target from $105 to $90.

As previously disclosed, on August 21, 2024, Liquidia Corporation, a Delaware corporation (the "Company") filed a lawsuit in the U.S. District Court of the District of Columbia (the "District Court") (Case No. 1:24-cv-02428)&nbsp;to challenge the decision by the U.S. Food and Drug Administration (the "FDA") to grant 3-year new clinical investigation exclusivity ("regulatory exclusivity") to Tyvaso DPI (the "FDA Litigation"). The District Court granted the parties' motion for an expedited summary judgment briefing schedule, and a summary judgment hearing was held on December 5, 2024.&nbsp; On February 27, 2025, the District Court issued a decision denying the Company's motion for summary judgment and simultaneously granting the motions for summary judgment filed by the FDA and United Therapeutics Corporation ("United Therapeutics").&nbsp; In so doing, the District Court affirmed the FDA's award of regulatory exclusivity to Tyvaso DPI.&nbsp; This decision does not affect the expiration of the regulatory exclusivity, which will still occur on May 23, 2025.
&nbsp;
United Therapeutics also filed a cross claim in the FDA Litigation, re-asserting its challenge to FDA's acceptance of the Company's amended New Drug Application ("NDA") for review.&nbsp; The Company intervened and became a party with respect to the cross claim on November 5, 2024.&nbsp; Both the Company and the FDA filed motions to dismiss United Therapeutics' cross claim.&nbsp; Those motions remain pending with the District Court and are unaffected by the decision issued by the District Court on February 27, 2025.

Legal

LQDA

Liquidia Litigation Against FDA Over Tyvaso DPI Exclusivity Denied; United Therapeutics' Cross Claim Remains Pending; Exclusivity Expires May 23, 2025

Comments

CONX Stock News

News

Latest CONX Stock News | OTC:CNXX | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga